Taken together, our data provides convincing evidence that BITC inhibits pancreatic tumor angiogenesis by targeting STAT-3 and inhibiting HIF-1α/VEGF/MMP-2/Rho-GTPases. This evidence concerns the gene VEGFA and pancreatic neoplasm.